Int. J. Mol. Sci. 2013, 14(12), 23685-23699; doi:10.3390/ijms141223685
Article

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score

1 Department of Surgery, Gananam Severance Hospital, Yonsei University College of Medicine, Seoul 135720, Korea 2 Department of Surgery, Eulji General Hospital, Eulji University College of Medicine, Seoul 139872, Korea 3 Department of Biology, College of Natural Science, Dong-A University, Busan 604714, Korea 4 Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejon 305806, Korea
* Author to whom correspondence should be addressed.
Received: 30 August 2013; in revised form: 15 November 2013 / Accepted: 19 November 2013 / Published: 4 December 2013
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
PDF Full-text Download PDF Full-Text [987 KB, uploaded 4 December 2013 11:36 CET]
Abstract: The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.
Keywords: breast cancer; estrogen receptor; recurrence score; 70-gene signature; FOXM1; AURKA; AURKB; BIRC5

Supplementary Files

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ahn, S.G.; Lee, H.M.; Lee, H.W.; Lee, S.A.; Lee, S.-R.; Leem, S.-H.; Jeong, J.; Chu, I.-S. Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score. Int. J. Mol. Sci. 2013, 14, 23685-23699.

AMA Style

Ahn SG, Lee HM, Lee HW, Lee SA, Lee S-R, Leem S-H, Jeong J, Chu I-S. Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score. International Journal of Molecular Sciences. 2013; 14(12):23685-23699.

Chicago/Turabian Style

Ahn, Sung G.; Lee, Hak M.; Lee, Hak W.; Lee, Seung A.; Lee, Se-Ra; Leem, Sun-Hee; Jeong, Joon; Chu, In-Sun. 2013. "Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score." Int. J. Mol. Sci. 14, no. 12: 23685-23699.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert